INVESTOR FACT SHEET

We are a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.

OUR STRATEGY

Create value by generating high growth and profitability of our rare disease medicines

Successful and proven commercial execution that optimizes the growth trajectory of our acquired medicines

Significantly Improved KRYSTEXXA® Growth



Uniquely strong in-house M&A capability with proven track record of execution

Recent Acquisitions

River Vision Development Corp.
May 2017
Added teprotumumab, a late-stage development biologic, to our clinical development pipeline

Raptor Pharmaceutical Corp.
October 2016
Added PROCYSBI® and QUINSAIR™, both rare disease medicines, to our Orphan business unit

Crealta Holdings LLC
January 2016
Added KRYSTEXXA®, a rare disease medicine for refractory chronic gout, to our Rheumatology business unit

Growing pipeline of differentiated and clinically relevant medicines with a focus on rare diseases

Driving Additional Growth With Our Rare Disease Focused Pipeline

Medicine	Treatment/Trial Objective	Pre-clinical	Phase 1	Phase 2	Phase 3	Post-market
Teprotumumab[1]	• Moderate to severe thyroid eye disease				●····●[2]	
ACTIMMUNE®	• Autosomal dominant osteopetrosis*			●		
	• Combo cancer therapy w/Opdivo®[3]*		●			
	• Combo cancer therapy w/Keytruda®[4]*			····●[5]		
	• Breast cancer combo cancer therapy[6]*		●			
KRYSTEXXA®	• TRIPLE trial* to address immunogenicity evaluating; initial dose, dosing frequency and increased dose based on weight					●
RAVICTI®	• Label expansion: UCD in patients from birth to 2 months of age					●
RAYOS®	• Lupus* (to address fatigue)					●

Rare Disease Medicine

Other

*Investigator-initiated trial

Purposeful Transition to Rare Disease Medicines Company

First Half 2013:

2 Medicines;
Net Sales of $16M

DUEXIS® (ibuprofen and famotidine) Tablets 800 mg/26.6 mg

RAYOS® (Prednisone) Delayed-release Tablets

First Half 2017:

11 Medicines, 6 for Rare Diseases;
Net Sales of $510M



Net Sales
(showing acquisitions)

Annual Net Sales ($M)



Executive Management

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Robert F. Carey
Executive Vice President, Chief Business Officer

Paul W. Hoelscher
EVP, Chief Financial Officer

Barry J. Moze
EVP, Chief Administrative Officer

Brian K. Beeler
EVP, General Counsel

Jeffrey W. Sherman, M.D., FACP
EVP, Research and Development and Chief Medical Officer

Michael DesJardin
EVP, Technical Operations and Corporate Quality

Dave Happel
EVP, Commercial Development and Strategy

George Hampton
EVP, Primary Care Business Units

Vikram Karnani
SVP, Rheumatology Business Unit

Irina Konstantinovsky
EVP, Chief Human Resources Officer

Eric Mosbrooker
SVP, Orphan Business Unit

David G. Kelly
EVP, Company Secretary and Managing Director, Ireland

Board of Directors

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Michael Grey
Lead Independent Director

Liam Daniel

Jeff Himawan, Ph.D.

Ronald Pauli

Gino Santini

James Shannon, M.D.

H. Thomas Watkins

Pascale Witz

Key Figures

Closing Share Price (8/31/17):	$13.68
Market Capitalization:	$2.3B
Ordinary Shares Outstanding:	164.9M
Global Employees:	>1,050

For safety information, see product websites:

www.ACTIMMUNE.com
For BUPHENYL: www.horizonpharma.com
www.DUEXIS.com
www.KRYSTEXXA.com
www.MIGEROT.com
www.PENNSAID.com
www.PROCYSBI.com
www.RAVICTI.com
www.RAYOSrx.com
www.VIMOVO.com

Corporate Headquarters	U.S. Operations	Investor Relations Contacts		Corporate Media Contact	Ireland Media Contact
Connaught House, 1st Floor 1 Burlington Road Dublin 4, Ireland DO4 C5Y6 +353 1 772 2100	150 S Saunders Road Lake Forest, IL 60045 +1 224 383 3000	**Tina Ventura** investor-relations@horizonpharma.com	**Ruth Venning** investor-relations@horizonpharma.com	**Geoffrey Curtis** media@horizonpharma.com	**Ray Gordon** ray@gordonmrm.ie

(1) Teprotumumab is a development-stage biologic and is not approved for use. (2) Expect to begin Phase 3 study by year end. (3) Registered trademark of Bristol-Myers Squibb. (4) Registered trademark of Merck. (5) Expect to initiate Phase 2 program by year end. (6) Study with Taxol, Herceptin and Perjeta; Taxol is a registered trademark of Bristol-Meyers Squibb. Herceptin and Perjeta are registered trademarks of Genentech. (7) PROCYSBI and QUINSAIR were acquired on Oct. 25, 2016. Horizon Pharma divested the marketing rights to PROCSYBI and QUINSAIR in Europe, the Middle East and Africa on June 23, 2017. Horizon Pharma retains marketing rights for the two medicines in the U.S., Canada, Latin America and Asia. QUINSAIR is not approved in the United States. (8) 2016 Net Sales is an adjusted, non-GAAP measure; excludes $65 million from GAAP net sales representing a litigation payment in 2016.

This fact sheet is a summary of more detailed disclosure that can be found in Horizon's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Horizon's most recent forms 10-K, 10-Q, and 8-K. The information in this fact sheet is given as of August 31, 2017, and Horizon does not undertake any obligation to update any information in this document.